Fed. Circ. Upholds Genzyme’s Win In Stem Cell Patent Case

Law360, New York (December 18, 2017, 7:04 PM EST) -- The Federal Circuit on Monday affirmed a Delaware federal judge’s finding in a bench trial that a Genzyme Corp. patent on harvesting stem cells is valid, leaving in place a ruling that barred generic versions of the cancer drug Mobozil planned by Dr. Reddy’s and Teva.

The appeals court found that Judge Gregory Sleet of the District of Delaware was correct when he concluded that Genzyme’s patent was not rendered obvious by a journal article and earlier patents. The generics makers conceded that their versions would...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.